气管炎丸在支气管哮喘治疗中的作用

Bronchitis pill's role in the treatment of bronchial asthma

目的:分析并评价中药气管炎丸在支气管哮喘治疗中的作用以及临床疗效。方法:将我院自2008年2月～2010年12月期间收治的140例符合标准的住院支气管哮喘病人按分组先后编号,以随机数字表法分为治疗组与对照组各70例。对照组进行常规西医治疗;治疗组在常规西医治疗基础上再给予中药气管炎丸进行治疗。结果:治疗组显效率为72.85%,明显高于对照组显效率48.57%,在临床疗效方面治疗组优于对照组,差异显著(P<0.05),具有统计学意义。对照组的FEV1和FEV1%均明显高于治疗组,差异显著(P<0.05),具有统计学意义。对照组的最大呼气流速(PEFR)高于治疗组,但两组间差异不显著(P>0.05),不具有统计学意义。结论:在西医常规治疗的基础上再应用中药气管炎丸治疗支气管哮喘的临床疗效明显优于单一的西医常规治疗,气管炎丸治疗支气管哮喘疗效理想,值得临床广泛推广应用。

Objective： An analysis and evaluation of the Chinese herbal medicine tracheitis pill in the treatment of bronchial asthma and clinical efficacy. Methods： From February 2008 to December 2010 treated 140 patients with standard hospital in patients of bronchial asthma by grouping has numbered to randomly divided into the treatment group and the control group with 70 cases in each group. The control group routine treatment of Western medicine; the treatment group was treated with routine western medicine therapy on the basis of TCM to treat tracheitis pill. Results： The treatment group significant efficiency was 72.85%, significantly higher than that in control group markedly effective rate was 48.57%, the clinical efficacy in treatment group than in control group, the difference is significant （P〈0.05）, with statistical significance. The control group of FEV1 and FEVI% were significantly higher than the treatment group, had significant difference （P〈0.05）, with statistical significance. The control group of peak expiratory flow rate （PEFR） was higher than that of the treatment group, but the difference between the two groups was not significant （P〉0.05）, no statistically significant. Conclusion： Routine treatment of western medicine on the basis of using the traditional Chinese medicine tracheitis pill in treating bronchial asthma clinical curative effect is obviously superior to the single conventional western medicine treatment, tracheitis pill in treating bronchial asthma, and wide application in clinic.